MedTrace Logo

Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

NCT00003614 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-06-15

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of paclitaxel plus estramustine in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.

Conditions

Interventions

DRUG

estramustine phosphate sodium

DRUG

paclitaxel

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Eastern Cooperative Oncology Group

    lead NETWORK

Principal Investigators

  • Gary R. Hudes, MD · Fox Chase Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-02-04
Primary Completion
2005-04-30

Countries

  • United States
  • South Africa

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003614 on ClinicalTrials.gov